SM
CTXR icon

Sabby Management’s Citius Pharmaceuticals CTXR Stock Holding History

Sabby Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-34
Closed -$129K – 163
2021
Q4 		$129K Buy
34
+14
+70% +$635 0.02% 147
2021
Q3 		$100K Buy
+20
New +$1K 0.01% 159

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Sabby Management's CTXR Position: Q1 2022 in Review

Sabby Management sold out of Citius Pharmaceuticals (CTXR) in Q1 2022, closing a stake of 1,235 shares — an estimated $48K sold.

Sabby Management first reported a position in CTXR in Q4 2017 and held it in 10 quarters. The position peaked at $1.99M in Q1 2018. 76 funds tracked by Wall St. Rank hold CTXR as of Q1 2022.

  • Sabby Management reported no remaining Citius Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Sabby Management sold 1,235 Citius Pharmaceuticals shares in Q1 2022, an estimated $48K.
  • Sabby Management first reported a position in Citius Pharmaceuticals in Q4 2017 and held it in 10 quarters.
  • Sabby Management's Citius Pharmaceuticals position peaked at $1.99M in Q1 2018.
  • 76 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.